AndrewFarbMD

PubMed

• 3 citations
  Standardized Definitions for Cardiogenic Shock Research and Mechanical Circulatory Support Devices: Scientific Expert Panel From the Shock Academic Research Consortium...
  Ron Waksman, Mohit Pahuja, Sean van Diepen, Alastair G Proudfoot, David Morrow, Ernest Spitzer, Graham Nichol, Myron L Weisfeldt, Mauro Moscucci, Patrick R Lawler, Ale...> ;Circulation. 2023 Oct 3
• 1 citations
  The medical device development ecosystem: Current regulatory state and challenges for future development: A review.
  David R Holmes Jr, Andrew Farb, Nabil Dib, Louis Jacques, Stanton Rowe, Anthony DeMaria, Spencer King, Bram Zuckerman> ;Cardiovascular Revascularization Medicine. 2024 Mar 1
• Consensus minimum core data elements adapted to peripheral vascular intervention in the drug-eluting era: Consensus report from the Registry Assessment of Peripheral I...
  James H Black 3rd, Donna Buckley, Martha Velezis, Jens Eldrup-Jorgensen, Nina D Serratore, Jorge A Gutierrez, Eleni Whatley, Rebecca A Marmor, Daniel J Bertges, James ...> ;Journal of Vascular Surgery. 2023 Nov 1
• 1 citations
  Diversity in Clinical Trial Enrollment and Reporting-Where We Are and the Road Ahead.
  Andrew Farb, Charles J Viviano, Michelle E Tarver> ;JAMA Cardiology. 2023 Sep 1
• 9 citations
  Comparative Effectiveness of Percutaneous Microaxial Left Ventricular Assist Device vs Intra-Aortic Balloon Pump or No Mechanical Circulatory Support in Patients With ...
  Zaid I Almarzooq, Yang Song, Issa J Dahabreh, Ajar Kochar, Enrico G Ferro, Eric A Secemsky, Jacqueline M Major, Andrew Farb, Changfu Wu, Bram Zuckerman, Robert W Yeh> ;JAMA Cardiology. 2023 Aug 1
• Early feasibility studies in the United States: Focus on electrophysiology.
  J Peter Weiss, Andrew Farb> ;Journal of Cardiovascular Electrophysiology. 2023 Oct 1
• 3 citations
  Development and validation of an automated algorithm for end point adjudication for a large U.S. national registry.
  Daniel J Friedman, Dominique Pierre, Yongfei Wang, Louise Gambone, Christina Koutras, Claire Segawa, Andrew Farb, Sreekanth Vemulapalli, Paul D Varosy, Frederick A Mas...> ;American Heart Journal. 2022 Dec 1
• 1 citations
  One-Year Follow-Up of Vascular Intervention Trials Disrupted by the COVID-19 Pandemic: A Use-Case landscape.
  Jennifer A Rymer, Ajay J Kirtane, Andrew Farb, Misti Malone, Michael R Jaff, Kirk Seward, Dan Stephens, Mark K Barakat, Mitchell W Krucoff> ;Cardiovascular Revascularization Medicine. 2022 Dec 1
• Noninferiority Margins in Clinical Trials-A Moving Target?
  Li Wang, Rebecca Torguson, Andrew Farb> ;JAMA Cardiology. 2022 Mar 1
• 99 citations
  Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations.
  Luiz F. Ybarra, Stéphane Rinfret, Emmanouil S. Brilakis, Dimitri Karmpaliotis, Lorenzo Azzalini, J. Aaron Grantham, David E. Kandzari, Kambis Mashayekhi, James C. Spra...> ;Circulation. 2021 Feb 2
• 6 citations
  Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessmen...
  Aaron E. Lottes, Eleni M. Whatley, Sara M. Royce, Daniel J. Bertges, Carla A. Erickson, Andrew Farb, Megan L. Fox, Jenny H. Jiang, Li Wang, Asiyah Y. Lin, Misti L. Mal...> ;American Heart Journal. 2021 Feb 1
• 3 citations
  Early Feasibility Studies for Cardiovascular Devices in the United States: JACC State-of-the-Art Review.
  David R. Holmes, Andrew Farb, Robert “Chip” Hance, Pamela Goldberg, Bram D. Zuckerman, Aaron V. Kaplan, Liliana Rincon-Gonzalez, Jon Hunt, Jaime Walkowiak, Michael J. ...> ;Journal of the American College of Cardiology. 2020 Dec 8
• 12 citations
  Cardiac safety research consortium “shock II” think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock
  Marc D. Samsky, Mitchell W. Krucoff, David A. Morrow, William T. Abraham, Fernando Aguel, Andrew D. Althouse, Eric Chen, Joaquin E. Cigarroa, Adam D. DeVore, Andrew Fa...> ;American Heart Journal. 2020 Oct 2
• 202 citations
  Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;European Heart Journal. 2019 Aug 14
• 7 citations
  The 21st Century Cures Act and Early Feasibility Studies for Cardiovascular Devices: What Have We Learned, Where Do We Need to Go?
  David R. Holmes, Robert “Chip” Hance, Tamara Syrek Jensen, Daniel A. Schwartz, Aaron V. Kaplan, Andrew Farb, Bram D. Zuckerman, Jamie Waklowiak, Michael J. Mack, Jeff ...> ;JACC. Cardiovascular Interventions. 2018 Nov 12
• 253 citations
  Standardized End Point Definitions for Coronary Intervention Trials
  Hector M. Garcia-Garcia, Eugene P. McFadden, Andrew Farb, Roxana Mehran, Gregg W. Stone, John A. Spertus, Yoshinobu Onuma, Marie-Angèle Morel, Gerrit-Anne van Es, Bram...> ;European Heart Journal. 2018 Jun 14
• 144 citations
  2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.
  Karen A Hicks, Kenneth W Mahaffey, Roxana Mehran, Steven E Nissen, Stephen D Wiviott, Billy Dunn, Scott D Solomon, John R Marler, John R Teerlink, Andrew Farb, David A...> ;Journal of the American College of Cardiology. 2018 Mar 6
• 138 citations
  2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.
  Karen A Hicks, Kenneth W Mahaffey, Roxana Mehran, Steven E Nissen, Stephen D Wiviott, Billy Dunn, Scott D Solomon, John R Marler, John R Teerlink, Andrew Farb, David A...> ;Circulation. 2018 Feb 27
• 12 citations
  Clinical event adjudication in cardiovascular device trials: An Food and Drug Administration perspective.
  Andrew Farb, Bram Zuckerman> ;American Heart Journal. 2017 May 23
• First Device to Market: Highlighting the Value of the US Early Feasibility Study Program.
  Jose Pablo Morales, Andrew Farb> ;Journal of Vascular and Interventional Radiology. 2017 Sep 1
• 16 citations
  Overcoming the Challenges of Conducting Early Feasibility Studies of Medical Devices in the United States
  David R. Holmes, Robert M. Califf, Andrew Farb, Dorothy Abel, Michael J. Mack, Tamara Syrek Jensen, Bram D. Zuckerman, Jeff Shuren> ;Journal of the American College of Cardiology. 2016 Oct 25
• 6 citations
  Clinical Perspective--Early Feasibility Device Medical Studies in the United States: Time for More Than Regulatory Reform.
  David R. Holmes, Jeff Shuren, Robert M. Califf, Bram Zuckerman, Dorothy B. Abel, Andrew Farb, Michael J. Mack> ;JACC. Cardiovascular Interventions. 2016 Mar 28
• 3 citations
  New technology in electrophysiology: FDA process and perspective.
  Kimberly A. Selzman, Mark Fellman, Andrew Farb, Sergio de Del Castillo, Bram Zuckerman> ;Journal of Interventional Cardiac Electrophysiology. 2016 Mar 28
• 15 citations
  Current challenges for clinical trials of cardiovascular medical devices
  Faiez Zannad, Wendy Gattis Stough, Ileana L. Piña, Roxana Mehran, William T. Abraham, Stefan D. Anker, Gaetano M. De Ferrari, Andrew Farb, Nancy L. Geller, Robert S. K...> ;International Journal of Cardiology. 2014 Jul 15
• 47 citations
  Pathology of drug-eluting versus bare-metal stents in saphenous vein bypass graft lesions.
  Saami K. Yazdani, Andrew Farb, Masataka Nakano, Marc Vorpahl, Elena Ladich, Aloke V. Finn, Frank D. Kolodgie, Renu Virmani> ;JACC. Cardiovascular Interventions. 2012 Jun 1
• Join now to see all

Journal Articles

• The 21st Century Cures Act and Early Feasibility Studies for Cardiovascular Devices  
  Aaron Kaplan, Martin Leon, Michael J Mack, Andrew Farb, ScienceDirect

Lectures

• The US EFS and Breakthrough Devices Programs: An FDA Update 
  CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/26/2019